+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Clostridium Difficile Infection Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 190 Pages
  • July 2025
  • Region: Global
  • Fairfield Market Research
  • ID: 5925048
The global Clostridium difficile infection treatment market size is likely to be valued at US$ 1.2 Bn in 2025 and is estimated to reach US$ 2 Bn by 2032, growing at a CAGR of 7.57% during the forecast period from 2025 to 2032. Rising incidence of healthcare-associated infections, growing antibiotic resistance, and an aging population are contributing significantly to the growth in CDI cases globally. Consequently, the demand for effective and targeted treatments has risen, supporting the market’s expansion.

Clostridium Difficile Infection Treatment Market - Report Scope:

The CDI treatment market comprises antibiotics such as metronidazole, vancomycin, and fidaxomicin, as well as innovative therapeutics including microbiome restoration therapies. With recurring CDI cases becoming more prevalent and traditional antibiotics facing limitations, new treatment approaches are gaining momentum. Oral formulations remain the most widely preferred route of administration, while hospital pharmacies continue to dominate distribution channels due to high patient inflow in healthcare settings.

Key Market Drivers:

Rising global CDI incidence, particularly in hospitalized patients and long-term care facilities, is a significant driver for the treatment market. Aging populations and the overuse of antibiotics further escalate the risk of infection and recurrence. The increasing adoption of targeted therapies such as fidaxomicin and microbiota-based therapeutics reflects the urgent need for effective and safer alternatives. Additionally, awareness campaigns and government efforts toward infection control are further accelerating market demand.

Market Restraints:

High cost of advanced therapies like fidaxomicin and fecal microbiota transplantation (FMT), particularly in low- and middle-income countries, continues to hinder market growth. Moreover, the limited availability of approved microbiota-based treatments and challenges in product standardization restrict wider adoption. Recurrence of CDI despite treatment and the lack of widespread diagnostic capabilities in some regions also act as restraints on market penetration.

Emerging Business Opportunities:

The development of microbiome-based therapeutics and novel antibiotics offers vast potential for reshaping CDI treatment paradigms. Companies exploring partnerships for FMT commercialization and oral microbiota capsules are likely to gain early-mover advantage. Furthermore, expanding access to CDI diagnostics and treatment options in emerging markets such as Asia Pacific and Latin America presents significant revenue opportunities. Increased funding for research into non-antibiotic therapies also signals a new wave of innovation.

Regional Outlook:

North America dominates the CDI treatment market due to high CDI incidence, advanced healthcare infrastructure, and early adoption of novel therapies. The U.S. leads the regional market owing to strong reimbursement frameworks and widespread clinical trials. Europe is witnessing steady growth with government-funded infection control programs and antibiotic stewardship initiatives. Asia Pacific is poised for rapid expansion fueled by improving healthcare access, increasing awareness, and growing elderly population. Latin America and Middle East & Africa represent emerging markets with untapped potential, particularly in hospital infection control and access to essential antibiotics.

Leading Companies:

Prominent players in the Clostridium difficile infection treatment market are focusing on innovation, strategic collaborations, and product expansion to strengthen their competitive edge. Companies like Merck & Co., Inc., Pfizer Inc., and Ferring Pharmaceuticals are investing heavily in clinical trials and novel formulations. Emerging players such as Seres Therapeutics, Inc., Vedanta Biosciences, Inc., and MGB Biopharma are introducing promising microbiome-based solutions and non-traditional therapies. Market consolidation, licensing agreements, and global distribution expansion remain key strategies for long-term success.

Companies Covered in This Report:

  • Merck & Co., Inc.
  • Baxter International Inc.
  • Pfizer Inc.
  • Astellas Pharma Inc.
  • Ferring Pharmaceuticals
  • Seres Therapeutics, Inc.
  • Vedanta Biosciences, Inc.
  • MGB Biopharma
  • Crestone, Inc.
  • Mylan N.V.
  • ANI Pharmaceuticals, Inc.
  • B. Braun Medical Inc.
  • Teva Pharmaceuticals USA, Inc.
  • Criticine Care
  • Eugia US
  • Meitheal® Pharmaceuticals
  • AdvaCare Pharma®
  • LGM Pharma

Market Segmentation:

By Drug Type

  • Metronidazole
  • Vancomycin
  • Fidaxomicin
  • Others

By Route of Administration

  • Oral
  • Injectable
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Clostridium Difficile Infection Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Clostridium Difficile Infection Treatment Market Outlook, 2019-2032
3.1. Global Clostridium Difficile Infection Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019-2032
3.1.1. Key Highlights
3.1.1.1. Metronidazole
3.1.1.2. Vancomycin
3.1.1.3. Fidaxomicin
3.2. Global Clostridium Difficile Infection Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
3.2.1. Key Highlights
3.2.1.1. Oral
3.2.1.2. Injectable
3.3. Global Clostridium Difficile Infection Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
3.3.1. Key Highlights
3.3.1.1. Hospital Pharmacies
3.3.1.2. Retail Pharmacies
3.3.1.3. Mail Order Pharmacies
3.4. Global Clostridium Difficile Infection Treatment Market Outlook, by Region, Value (US$ Bn), 2019-2032
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Clostridium Difficile Infection Treatment Market Outlook, 2019-2032
4.1. North America Clostridium Difficile Infection Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019-2032
4.1.1. Key Highlights
4.1.1.1. Metronidazole
4.1.1.2. Vancomycin
4.1.1.3. Fidaxomicin
4.2. North America Clostridium Difficile Infection Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
4.2.1. Key Highlights
4.2.1.1. Oral
4.2.1.2. Injectable
4.3. North America Clostridium Difficile Infection Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
4.3.1. Key Highlights
4.3.1.1. Hospital Pharmacies
4.3.1.2. Retail Pharmacies
4.3.1.3. Mail Order Pharmacies
4.4. North America Clostridium Difficile Infection Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
4.4.1. Key Highlights
4.4.1.1. U.S. Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
4.4.1.2. U.S. Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
4.4.1.3. U.S. Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
4.4.1.4. Canada Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
4.4.1.5. Canada Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
4.4.1.6. Canada Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Clostridium Difficile Infection Treatment Market Outlook, 2019-2032
5.1. Europe Clostridium Difficile Infection Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019-2032
5.1.1. Key Highlights
5.1.1.1. Metronidazole
5.1.1.2. Vancomycin
5.1.1.3. Fidaxomicin
5.2. Europe Clostridium Difficile Infection Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
5.2.1. Key Highlights
5.2.1.1. Oral
5.2.1.2. Injectable
5.3. Europe Clostridium Difficile Infection Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
5.3.1. Key Highlights
5.3.1.1. Hospital Pharmacies
5.3.1.2. Retail Pharmacies
5.3.1.3. Mail Order Pharmacies
5.4. Europe Clostridium Difficile Infection Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
5.4.1. Key Highlights
5.4.1.1. Germany Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
5.4.1.2. Germany Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
5.4.1.3. Germany Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.4. U.K. Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
5.4.1.5. U.K. Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
5.4.1.6. U.K. Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.7. France Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
5.4.1.8. France Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
5.4.1.9. France Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.10. Italy Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
5.4.1.11. Italy Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
5.4.1.12. Italy Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.13. Turkey Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
5.4.1.14. Turkey Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
5.4.1.15. Turkey Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.16. Russia Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
5.4.1.17. Russia Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
5.4.1.18. Russia Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1.19. Rest of Europe Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
5.4.1.20. Rest of Europe Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
5.4.1.21. Rest of Europe Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Clostridium Difficile Infection Treatment Market Outlook, 2019-2032
6.1. Asia Pacific Clostridium Difficile Infection Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019-2032
6.1.1. Key Highlights
6.1.1.1. Metronidazole
6.1.1.2. Vancomycin
6.1.1.3. Fidaxomicin
6.2. Asia Pacific Clostridium Difficile Infection Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
6.2.1. Key Highlights
6.2.1.1. Oral
6.2.1.2. Injectable
6.3. Asia Pacific Clostridium Difficile Infection Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
6.3.1. Key Highlights
6.3.1.1. Hospital Pharmacies
6.3.1.2. Retail Pharmacies
6.3.1.3. Mail Order Pharmacies
6.4. Asia Pacific Clostridium Difficile Infection Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
6.4.1. Key Highlights
6.4.1.1. China Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
6.4.1.2. China Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
6.4.1.3. China Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.4. Japan Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
6.4.1.5. Japan Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
6.4.1.6. Japan Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.7. South Korea Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
6.4.1.8. South Korea Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
6.4.1.9. South Korea Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.10. India Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
6.4.1.11. India Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
6.4.1.12. India Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.13. Southeast Asia Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
6.4.1.14. Southeast Asia Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
6.4.1.15. Southeast Asia Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1.16. Rest of Asia Pacific Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
6.4.1.17. Rest of Asia Pacific Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
6.4.1.18. Rest of Asia Pacific Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Clostridium Difficile Infection Treatment Market Outlook, 2019-2032
7.1. Latin America Clostridium Difficile Infection Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019-2032
7.1.1. Key Highlights
7.1.1.1. Metronidazole
7.1.1.2. Vancomycin
7.1.1.3. Fidaxomicin
7.2. Latin America Clostridium Difficile Infection Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
7.2.1. Key Highlights
7.2.1.1. Oral
7.2.1.2. Injectable
7.3. Latin America Clostridium Difficile Infection Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
7.3.1. Key Highlights
7.3.1.1. Hospital Pharmacies
7.3.1.2. Retail Pharmacies
7.3.1.3. Mail Order Pharmacies
7.4. Latin America Clostridium Difficile Infection Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
7.4.1. Key Highlights
7.4.1.1. Brazil Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
7.4.1.2. Brazil Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
7.4.1.3. Brazil Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.4.1.4. Mexico Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
7.4.1.5. Mexico Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
7.4.1.6. Mexico Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.4.1.7. Argentina Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
7.4.1.8. Argentina Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
7.4.1.9. Argentina Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.4.1.10. Rest of Latin America Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
7.4.1.11. Rest of Latin America Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
7.4.1.12. Rest of Latin America Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Clostridium Difficile Infection Treatment Market Outlook, 2019-2032
8.1. Middle East & Africa Clostridium Difficile Infection Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2019-2032
8.1.1. Key Highlights
8.1.1.1. Metronidazole
8.1.1.2. Vancomycin
8.1.1.3. Fidaxomicin
8.2. Middle East & Africa Clostridium Difficile Infection Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
8.2.1. Key Highlights
8.2.1.1. Oral
8.2.1.2. Injectable
8.3. Middle East & Africa Clostridium Difficile Infection Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
8.3.1. Key Highlights
8.3.1.1. Hospital Pharmacies
8.3.1.2. Retail Pharmacies
8.3.1.3. Mail Order Pharmacies
8.4. Middle East & Africa Clostridium Difficile Infection Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
8.4.1. Key Highlights
8.4.1.1. GCC Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
8.4.1.2. GCC Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
8.4.1.3. GCC Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.4.1.4. South Africa Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
8.4.1.5. South Africa Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
8.4.1.6. South Africa Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.4.1.7. Egypt Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
8.4.1.8. Egypt Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
8.4.1.9. Egypt Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.4.1.10. Nigeria Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
8.4.1.11. Nigeria Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
8.4.1.12. Nigeria Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.4.1.13. Rest of Middle East & Africa Clostridium Difficile Infection Treatment Market by Drug Type, Value (US$ Bn), 2019-2032
8.4.1.14. Rest of Middle East & Africa Clostridium Difficile Infection Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
8.4.1.15. Rest of Middle East & Africa Clostridium Difficile Infection Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Drug Type vs Route of Administration Heatmap
9.2. Company Market Share Analysis, 2025
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Merck & Co., Inc
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Baxter International Inc.
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Sanofi S.A.
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Pfizer Inc.
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Novartis AG
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Astellas Pharma
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Eli LilIy & Company
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. AstraZeneca
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. Actelion Pharmaceuticals Ltd (Sub. of Johnson & Johnson Services, Inc.)
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. Mylan N.V.
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

  • Merck & Co., Inc.
  • Baxter International Inc.
  • Pfizer Inc.
  • Astellas Pharma Inc.
  • Ferring Pharmaceuticals
  • Seres Therapeutics, Inc.
  • Vedanta Biosciences, Inc.
  • MGB Biopharma
  • Crestone, Inc.
  • Mylan N.V.
  • ANI Pharmaceuticals, Inc.
  • B. Braun Medical Inc.
  • Teva Pharmaceuticals USA, Inc.
  • Criticine Care
  • Eugia US
  • Meitheal® Pharmaceuticals
  • AdvaCare Pharma®
  • LGM Pharma